Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersOperating ExpensesOperating IncomeProfit After TaxResearch & DevelopmentSelling, General & AdministrativeTax ProvisionsTax RateTax Rate
Others
Ratios

Atea Pharmaceuticals (AVIR) Income towards Parent Company (2020 - 2022)

Atea Pharmaceuticals has reported Income towards Parent Company over the past 3 years, most recently at -$34.4 million for Q4 2022.

  • Quarterly results put Income towards Parent Company at -$34.4 million for Q4 2022, down 129.4% from a year ago — trailing twelve months through Dec 2022 was -$115.9 million (down 195.64% YoY), and the annual figure for FY2025 was -$158.3 million, up 5.96%.
  • Income towards Parent Company for Q4 2022 was -$34.4 million at Atea Pharmaceuticals, down from -$8.1 million in the prior quarter.
  • Over the last five years, Income towards Parent Company for AVIR hit a ceiling of $117.1 million in Q4 2021 and a floor of -$42.1 million in Q1 2022.
  • Median Income towards Parent Company over the past 3 years was -$9.0 million (2020), compared with a mean of -$472166.7.
  • Biggest five-year swings in Income towards Parent Company: skyrocketed 870.14% in 2021 and later plummeted 2136.06% in 2022.
  • Atea Pharmaceuticals' Income towards Parent Company stood at $20.7 million in 2020, then skyrocketed by 467.06% to $117.1 million in 2021, then tumbled by 129.4% to -$34.4 million in 2022.
  • The last three reported values for Income towards Parent Company were -$34.4 million (Q4 2022), -$8.1 million (Q3 2022), and -$31.3 million (Q2 2022) per Business Quant data.